STOCK TITAN
  1. Home
  2. News
  3. ZTS

ZOETIS INC. - ZTS STOCK NEWS

Welcome to our dedicated page for ZOETIS news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on ZOETIS stock.

Zoetis Inc. (symbol: ZTS) is a leading American pharmaceutical company and the world's largest producer of medicines and vaccinations for pets and livestock. Originally a subsidiary of Pfizer, Zoetis became an independent company following Pfizer’s spinoff of its 83% interest. Zoetis specializes in a wide range of products including anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals.

The company's revenue is split between production animals (cattle, pigs, poultry, etc.), which contribute approximately 35%, and companion animals (dogs, horses, cats), which account for nearly 65%. In the U.S., Zoetis' business is predominantly focused on companion animals, while its international operations have a slight inclination towards production animals. As an industry leader, Zoetis holds the largest market share and continues to lead in innovation and product development for animal health.

Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity. Financially, Zoetis remains robust with consistent revenue growth and strategic partnerships to expand its market reach. Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.

Stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. to make informed investment decisions.

News

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Zoetis Inc. (NYSE:ZTS) to host webcast and conference call to review Q4 and full year 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
conferences earnings
-
News

Zoetis to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Zoetis Inc. (NYSE:ZTS) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. Investors and other interested parties can access a live audio webcast of the presentation on http://investor.zoetis.com/events-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
conferences
-
News

Zoetis Declares First Quarter 2024 Dividend; Board Approves 15% Payment Increase

Rhea-AI Summary
Zoetis Inc. (ZTS) declares a dividend of $0.432 per share for the first quarter of 2024, an increase of 15% from 2023. The dividend will be paid on March 1, 2024, to all holders of record of the Company’s common stock as of January 19, 2024. Executive Vice President and CFO Wetteny Joseph attributes the increase to Zoetis' strong performance and commitment to returning excess capital to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
dividends earnings
News

Zoetis to Participate in the Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Summary
Zoetis Inc. (ZTS) will participate in the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023. Wetteny Joseph, EVP and CFO, will represent the company. Investors can access a live webcast of the presentation on the Zoetis website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences
-
News

Petco Love Announces Newest Board Members

Rhea-AI Summary
Petco Love: Bolsters Board to Better Serve Pet Lovers Nationwide - Welcomes New Members to Support Lifesaving Mission
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
management
-
News

Zoetis Announces Third Quarter 2023 Results

Rhea-AI Summary
Zoetis Inc. reports revenue of $2.2 billion, growing 7% in Q3 2023. Net income increases 13% to $596 million. Adjusted net income reaches $629 million, a 13% increase. Full-year 2023 revenue guidance range updated to $8.475 - $8.550 billion. Operational revenue growth guidance narrowed to 6.5% - 7.5% and adjusted net income growth to 7.5% - 8.5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
earnings
News

Zoetis Declares Fourth Quarter 2023 Dividend

Rhea-AI Summary
Zoetis Inc. declares $0.375 per share dividend for Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
dividends earnings
-
News

Zoetis Named a 100 Best Company for Working Parents by Seramount

Rhea-AI Summary
Zoetis named one of Seramount's 100 Best Companies for Working Parents for the tenth year in a row
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
News

Zoetis to Host Webcast and Conference Call on Third Quarter 2023 Financial Results

Rhea-AI Summary
Zoetis Inc. will host a webcast and conference call to review Q3 2023 financial results on Nov. 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
conferences earnings
News

Zoetis Foundation Announces $2.6 Million in Grants to Advance Opportunities for Veterinarians and Livestock Farmers

Rhea-AI Summary
The Zoetis Foundation will distribute $2.6 million in grants to support initiatives in Australia, Brazil, the UK, and the US. The grants will focus on veterinary scholarships and debt relief, mental well-being, diversity and inclusion, and livestock farmers' livelihoods. The Foundation is expanding its support for veterinary mental health and wellness. The grants will provide financial support and resources to veterinary professionals and farmers, addressing important issues such as student debt and mental health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none

FAQ

What is the current stock price of ZOETIS (ZTS)?

The current stock price of ZOETIS (ZTS) is $165.9 as of January 6, 2025.

What is the market cap of ZOETIS (ZTS)?

The market cap of ZOETIS (ZTS) is approximately 74.1B.

What does Zoetis Inc. specialize in?

Zoetis Inc. specializes in medicines and vaccinations for pets and livestock, including anti-infectives, vaccines, parasiticides, diagnostics, and other health products.

Is Zoetis Inc. still part of Pfizer?

No, Zoetis Inc. became an independent company after Pfizer spun off its 83% interest.

What percentage of Zoetis' revenue comes from companion animals?

Nearly 65% of Zoetis' revenue comes from companion animal products such as those for dogs, horses, and cats.

Which segment contributes more to Zoetis' U.S. business?

Zoetis' U.S. business is heavily skewed toward companion animals.

How does Zoetis' international business differ from its U.S. business?

Internationally, Zoetis' business is slightly skewed towards production animals, unlike its U.S. business, which focuses more on companion animals.

What recent achievements has Zoetis Inc. accomplished?

Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity.

What are Zoetis' current projects?

Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.

What is Zoetis' market position in the industry?

Zoetis holds the largest market share in the animal health industry.

Does Zoetis have any strategic partnerships?

Yes, Zoetis has strategic partnerships to expand its market reach and foster innovation.

Where can I find the latest updates on Zoetis Inc.?

You can stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. on StockTitan and other financial news platforms.
Stock ZTS logo
ZOETIS INC.

NYSE:ZTS

ZTS Rankings

#181 Ranked by Market Cap
#1733 Ranked by Dividends

ZTS Stock Data

74.09B
450.25M
0.2%
95.83%
1.39%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
PARSIPPANY